Patents by Inventor Haiyu Yu
Haiyu Yu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10294236Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cType: GrantFiled: December 11, 2017Date of Patent: May 21, 2019Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Mui Cheung, Michael P. Demartino, Hilary Schenck Eidam, Huiping Amy Guan, Donghui Qin, Chengde Wu, Zhen Gong, Haiying Yang, Haiyu Yu, Zhiliu Zhang
-
Publication number: 20180099976Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cType: ApplicationFiled: December 11, 2017Publication date: April 12, 2018Inventors: Mui Cheung, Michael P. Demartino, Hilary Schenck Eidam, Huiping Amy Guan, Donghui Qin, Chengde Wu, Zhen Gong, Haiying Yang, Haiyu Yu, Zhiliu Zhang
-
Patent number: 9879021Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cType: GrantFiled: September 10, 2015Date of Patent: January 30, 2018Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Mui Cheung, Michael P. Demartino, Hilary Schenck Eidam, Huiping Amy Guan, Donghui Qin, Chengde Wu, Zhen Gong, Haiying Yang, Haiyu Yu, Zhiliu Zhang
-
Publication number: 20170298074Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cType: ApplicationFiled: September 10, 2015Publication date: October 19, 2017Inventors: Mui CHEUNG, Michael P. DEMARTINO, Hilary Schenck EIDAM, Huiping Amy GUAN, Donghui QIN, Chengde WU, Zhen GONG, Haiying YANG, Haiyu YU, Zhiliu ZHANG
-
Publication number: 20150099762Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cType: ApplicationFiled: December 9, 2014Publication date: April 9, 2015Inventors: Hilary Schenck EIDAM, Kaushik RAHA, Zhen GONG, Huiping Amy GUAN, Chengde WU, Haiying YANG, Haiyu YU, Zhiliu ZHANG, Mui CHEUNG
-
Patent number: 8937071Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cType: GrantFiled: March 14, 2014Date of Patent: January 20, 2015Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Hilary Schenck Eidam, Kaushik Raha, Zhen Gong, Huiping Amy Guan, Chengde Wu, Haiying Yang, Haiyu Yu, Zhiliu Zhang, Mui Cheung
-
Publication number: 20140275111Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cType: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: GlaxoSmithKline Intellectual Property Development LimitedInventors: Hilary Schenck EIDAM, Kaushik Raha, Zhen Gong, Huiping Guan, Chengde Wu, Haiying Yang, Haiyu Yu, Zhiliu Zhang, Mui CHEUNG
-
Publication number: 20120083489Abstract: The invention provides novel bis-pyridylpyridones which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), pharmaceutical compositions containing them, processes for their preparation, and their use in therapy and for the treatment of obesity and diabetes.Type: ApplicationFiled: June 2, 2010Publication date: April 5, 2012Inventors: Siegfried Benjamin Christensen IV, Donghui Qin, Shenglin Chen, Xing Huang, Di Li, Fei Li, Lei Li, Xiaojuan Lin, Shi Lu, Zhen Lu, Maoyun Lv, Chuanning Wang, Chengde Wu, Mei Xiao, Haiyu Yu, Weina Zhang, Zhiliu Zhang
-
Patent number: 8149577Abstract: The present invention relates to a self-cooled thyistor device for ultra-high voltage fault current limiter. a self-cooled thyristor valve, it adopts horizontal structure consisted by frames, frames is divided into upper and below two spaces by crossbeams, the bottom of frames is supported by insulators. There is a cross plate between two vertical said frames, the cross plate mounts resistors connect with a high potential plate and capacitor through two wires. There is a thyistor string in said frame upper space, which is constituted of thyistors and cooler series. The thyistor string is compressed tightly by press-fit mechanism, thyistor string crosses current transformers. There are high potential plates on both sides of the thyistor, the number of the potential plates is equal to that of thyistor. One side of the high potential plates links frames, said current transformers connects with high potential plates.Type: GrantFiled: December 18, 2009Date of Patent: April 3, 2012Assignee: China Electric Power Research InstituteInventors: Guangfu Tang, Yuanliang Lan, Huafeng Wang, Hongzhou Luan, Zhiqi Li, Haiyu Yu, Huaxin Wang, Jing Zhang
-
Patent number: 8089330Abstract: The present invention provides a novel direct current thyristor valve saturated reactor includes: case, winding in the case, iron cores, cooling fins, pipes and press fit mechanism. The iron cores are coupled with winding. The invention having the following advantages: simple, modular design, low connection capacity of the wingding, fixed dimension, winding and irons well-cooled, small noise and vibration. The saturated reactor is particularly suitable used as the positive saturated reactor for high voltage current thyristor valve.Type: GrantFiled: December 18, 2009Date of Patent: January 3, 2012Assignee: China Electric Power Research InstituteInventors: Jialiang Wen, Xiaoguang Wei, Haiyu Yu, Sheng Zhang
-
Publication number: 20110216518Abstract: The present invention relates to a self-cooled thyistor device for ultra-high voltage fault current limiter. a self-cooled thyristor valve, it adopts horizontal structure consisted by frames, frames is divided into upper and below two spaces by crossbeams, the bottom of frames is supported by insulators. There is a cross plate between two vertical said frames, the cross plate mounts resistors connect with a high potential plate and capacitor through two wires. There is a thyistor string in said frame upper space, which is constituted of thyistors and cooler series. The thyistor string is compressed tightly by press-fit mechanism, thyistor string crosses current transformers. There are high potential plates on both sides of the thyistor, the number of the potential plates is equal to that of thyistor. One side of the high potential plates links frames, said current transformers connects with high potential plates.Type: ApplicationFiled: December 18, 2009Publication date: September 8, 2011Applicant: CHINA ELECTRIC POWER RESEARCH INSTITUTEInventors: Guangfu Tang, Yuanliang Lan, Huafeng Wang, Hongzhou Luan, Zhiqi Li, Haiyu Yu, Huaxin Wang, Jing Zhang
-
Publication number: 20110175697Abstract: The present invention provides a novel direct current thyristor valve saturated reactor includes: case, winding in the case, iron cores, cooling fins, pipes and press fit mechanism. The iron cores are coupled with winding. The invention having the following advantages: simple, modular design, low connection capacity of the wingding, fixed dimension, winding and irons well-cooled, small noise and vibration. The saturated reactor is particularly suitable used as the positive saturated reactor for high voltage current thyristor valve.Type: ApplicationFiled: December 18, 2009Publication date: July 21, 2011Applicant: CHINA ELECTRIC POWER RESEARCH INSTITUTEInventors: Jialiang Wen, Xiaoguang Wei, Haiyu Yu, Sheng Zhang